Vilon Dosage Chart: KE Dipeptide Course Protocol

Vilon has no validated human dose. It is a synthetic dipeptide (Lys-Glu, the KE sequence) sold as a research chemical, and the numbers circulating online trace to a Russian short-course convention — a 10-20 day course of small daily subcutaneous or intramuscular injections, repeated once or twice a year — not to any Western dose-ranging trial. This guide separates that convention from what was actually studied.

Vilon is one of the most-studied of Vladimir Khavinson's short peptide bioregulators, and it sits in the same thymic lineage as Thymalin and Thymogen. That lineage matters for reading dose claims: the human clinical work in this family was done on the tissue extracts, while Vilon is the synthetic two-amino-acid analog. Extract dosing does not transfer to the synthetic, and the synthetic dipeptide has essentially no independent Western data of its own.

Research-context information only. Vilon is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Vilon is a synthetic Lys-Glu dipeptide studied in rodent and cell-culture models for immune and geroprotective effects. The sections below cover the course convention, routes, reconstitution math for the 20 mg vial, and the honest provenance of every figure.

Quick Reference: Protocol

There is no Jay Campbell/Hunter Williams cheat-sheet entry for Vilon and no validated human dose, so the table below reflects the course convention carried through the Khavinson bioregulator literature and community research-chemical use — not a recommended schedule.

Community-reported variation (label: community/anecdotal — not from controlled trials): research-chemical protocols commonly describe a low-milligram subcutaneous amount once daily across a 10-20 day course. There is a wide gap between those amounts and the microgram-scale doses of the original Russian clinical Vilon, and nothing in the controlled literature validates either the amount or the route for the synthetic dipeptide. These figures are reported as community signal only.

Routes of Administration

• Subcutaneous (SC) — the route described in most community and vendor sources. Community reports frame SC as the convenient at-home route; it has no controlled-trial basis for Vilon specifically.
• Intramuscular (IM) and intranasal — the routes used in the original Russian clinical reports of the Vilon drug. No controlled study has established dose equivalence between these routes and community subcutaneous use.

The disambiguation matters when comparing route notes across sources: Vilon is a defined synthetic dipeptide (Lys-Glu), distinct from Thymalin (a crude thymus extract fraction) and Thymogen (the synthetic Glu-Trp dipeptide). Dose and route figures do not transfer between them.

Reconstitution Quick Reference

Community reconstitution guides describe bacteriostatic water for the 20 mg research-chemical vial, as with other research peptides. There is no validated concentration — the table below is a unit-conversion convention, not a dose.

At 10 mg/mL, 20,000 mcg divided by 2 mL is 10,000 mcg/mL — so a 2 mg amount draws to 0.2 mL (20 units) and a 5 mg amount to 0.5 mL (50 units) on a 100-unit insulin syringe. This is arithmetic that converts a chosen amount into syringe units; it is not a recommendation of what that amount should be. Community protocols describe swirling gently (not shaking), refrigerating at 2-8C, and using the reconstituted vial within 28 days.

For the full step-by-step mixing walkthrough, see our Vilon Reconstitution Guide.

Ready to buy? Compare verified vendors on our best Vilon sources page, or browse all coupon codes for up to 50% off.

Where These Numbers Come From

The dose convention above has no controlled human trial behind it. The Vilon evidence base is a small cluster of studies from a single research lineage — Vladimir Khavinson, Vladimir Anisimov, and colleagues associated with the St. Petersburg Institute of Bioregulation and Gerontology — and it is overwhelmingly preclinical or ex-vivo.

The most-cited animal report (Khavinson and Anisimov, Dokl Biol Sci, 2000; PMID 10944717) described the synthetic dipeptide inhibiting spontaneous tumor growth and increasing lifespan in mice. A related carcinogenesis study in rats (Pliss et al., Vopr Onkol, 2001; PMID 11785104) reported a fall in induced bladder-tumor incidence to 56% of treated animals versus 75.5% of controls. Both are single-group Russian animal studies from the compound's originators.

The proposed mechanism is gene-expression modulation. A DNA-microarray study of mouse heart tissue (S.V. Anisimov et al., Bull Exp Biol Med, 2002; PMID 12360356) reported that Vilon altered expression of 36 gene clones out of 15,247 examined — an originator finding framed as a hypothesis, not a settled pathway. The only human-derived work is ex-vivo cell culture: Vilon reportedly stimulated T-cell differentiation markers in cultured human and animal thymus cells (Sevostianova et al., Bull Exp Biol Med, 2013; PMID 23486604), and a chromatin study reported it induced deheterochromatinization and reactivated ribosomal genes in lymphocytes from elderly donors (Lezhava et al., Biogerontology, 2004; PMID 15105581).

Honest provenance summary: the Vilon data is old, single-lab, Russian, and not independently replicated in the West. The efficacy signals are rodent (anti-tumor, lifespan) and ex-vivo human (chromatin, thymus-cell differentiation) — there is no controlled human clinical trial and no validated dose. Every outcome above is the originators' reported finding, not established fact, and the human data that does exist in this family belongs to the tissue extracts, not the synthetic dipeptide.

Stacking Protocols

In the originating literature, Vilon was most often studied alongside Epithalon (the pineal peptide behind Epitalon) — given as separate agents, not mixed. The microarray and oncology studies that paired them treated the combination as its own experimental arm; a combined-arm signal is not evidence that either compound adds to the other, and both figures share the same non-independent dataset.

No Western trial has evaluated Vilon stacking. Community stacking claims beyond this documented pairing have no controlled support and are not reproduced here.

Side Effects & Safety

• The originating literature reports Vilon and related Khavinson peptides as well tolerated with "practically no side effects" — but that is an uncontrolled single-group claim from decades-old Russian use, not audited pharmacovigilance.
• Independent safety data is essentially absent — no large Western trials and no modern pharmacovigilance for the synthetic dipeptide.
• General research-chemical injectable risks apply: non-pharma-grade product, sterility and contamination risk, mislabeling or wrong-sequence risk, and injection-site reaction or infection.
• The proposed mechanism is gene-expression modulation; the long-term consequences of that are uncharacterized in any independent data, leaving a theoretical, unquantified concern.
• Not an approved drug in the West; sold only as a research chemical, not for human consumption.

For the fuller safety picture, see our Vilon Side Effects article. Framing: reported well-tolerated in older Russian use, but with no independent modern safety evaluation.